What is Bimzelx?
Bimzelx (also known by its generic name bimekizumab-bkzx) was approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Bimzelx is given by injection. For adults with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment), weeks 4, 8, 12, and 16, and then every 8 weeks afterward.
To learn more, please visit the Bimzelx website.
The first biologic targeting IL-17A and IL-17F is now approved for adults with moderate to severe plaque psoriasis.
The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.
